Special Issue "Zebrafish as a Powerful Tool for Drug Discovery 2021"
Deadline for manuscript submissions: 20 November 2020.
Interests: pharmacology; toxicology; integrative biology; zebrafish
Special Issues and Collections in MDPI journals
Interests: cancer modeling in zebrafish; xenografts; compound screening
Our scientific and technological knowledge has grown tremendously. The number of drugs approved relative to the costs, however, has continuously decreased. Various approaches have emerged to increase the efficacy of research and development of new drugs. It has been widely recognized that zebrafish can be powerful tools in the drug discovery field, given advantages such as high fecundity, ease of drug administration, similarity to mammals in terms of structures and functions of various tissues, and suitability for the 3Rs (replacement, reduction, and refinement). The process of drug development consists of multiple steps, including the initial discovery of drugs that can be used as therapeutics, preclinical, and clinical validation of their efficacy and toxicity, and the review, approval, and post-marketing surveillance of drugs by regulatory authorities. Using genome-editing technologies, genetic abnormalities observed in human diseases can be mimicked in zebrafish to make a disease model. The phenotypes of the disease model zebrafish can be used to identify novel compounds and/or new indications for old drugs (i.e., drug repositioning) that ameliorate the abnormal phenotypes of the zebrafish disease models. The toxicity of compounds can also be assessed using zebrafish. The International Council for Harmonization has considered including developmental toxicity testing using zebrafish in their guidelines. Zebrafish can also be integrated to validate the efficacy and toxicities of compounds that are identified as novel therapeutics by other approaches, such as computational drug discovery using big data. In this Special Issue, we invite authors to contribute articles focusing on zebrafish as powerful tools for drug discovery. This research topic will maximize the knowledge of the usefulness of zebrafish in drug development, with hopes of increasing the efficiency of the process and identifying drugs that can be used to prevent and/or treat diseases for which effective medications are currently lacking.
Prof. Yuhei Nishimura
Dr. Martin Distel
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- disease model
- drug repositioning
- computational biology